According to filings with the U.S. Securities and Exchange Commission, i-Lumen Scientific is raising $17,600,002.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, John VeLure played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About i-Lumen Scientific
i-Lumen Scientific is a retinal technology company, pioneering a new field in ophthalmics, designed to improve eyesight in patients whose vision has been impaired by nonexudative (dry) age-related macular degeneration (dAMD). This new therapy has the potential to address a large unmet patient need in the practice of ophthalmology. The i-LUMEN system and therapy, developed by i-Lumen Scientific, utilizes a revolutionary, non-invasive, software-based, medical device, to deliver proprietary pulsed microcurrent stimulation for the treatment of dry AMD. Macular degeneration is a highly debilitating visual disease, with no cure, and no cleared or approved treatments in the U.S. market for the treatment of dAMD. Now, with i-Lumen technology, there is finally hope for those afflicted with dry AMD.

To learn more about i-Lumen Scientific, visit http://www.i-lumen.com/

Contact:
John VeLure, Chief Executive Officer
612-845-3923
https://www.linkedin.com/in/john-velure-b336b0/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved